深部热疗结合化疗治疗晚期非小细胞肺癌疗效观察  

Study on Concomitant Deep Hyperthemia and Chemotherapy for Advanced Non-Small-Cell Lung Cancer

作　　者：王文辉[1] 蒲怀智[1] 雷小林[1] 汪宏云[1] 高泽莉[1] 

机构地区：[1]攀枝花学院附属医院肿瘤科,四川攀枝花617000

出　　处：《肿瘤预防与治疗》2009年第4期395-397,共3页Journal of Cancer Control And Treatment

摘　　要：目的:探讨深部热疗结合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效。方法:将65例经病理学或细胞学确诊的Ⅲ期或Ⅳ期不能手术的NSCLC患者按随机表分配法分成两组:热化组(33例)和单化组(32例),比较两组疗效及毒副反应。结果:单化组,总有效率(CR+PR)为37.50%(12/32),中位疾病进展时间(TP)6.5个月,中位生存时间9.5个月,1年生存率53.6%;热化组,总有效率(CR+PR)为 63.70%(21/33),中位疾病进展时间(TTP) 9. 6个月,中位生存时间15.3个月,1年生存率72.7%。两组疗效比较有统计学意义,P=0.035,两组毒副反应比较,均无统计学意义,P>0.05。结论:晚期非小细胞肺癌热化疗疗效优于单纯化疗。Objective： Objective： To study the efficacy of deep hyperthemia combined with chemotherapy for advanced non- small-cell lung cancer（NSCLC）. Methods： Sixty-five pathologically or cytologically confirmed NSCLC patients（ Ⅲ or Ⅳstage） who were not fit for operation were divided into 2 groups randomly： deep hyperthemia combined with chemotherapy group（ 33 cases） and chemotherapy group （32 cases） . The efficacy and side effects Were compared between these two groups. Results： For the chemotherapy group, the total effective rate（ CR ＋ PR） was 37.50% （12/32）, the median time to disease progression（TTP） was 6.5 months,the median survival time was 9.5 months and the 1-year survival rate was 53, 6%. For the deep hyperthemia combined with chemotherapy group, the total effective rate（ CR ＋ PR） was 63.70% （21/33）, TTP was 9.6 months,the median survival time was 15.3 months and the 1 -year survival rate was 72.2%. There was significant difference in efficacy between these two groups （ P = 0. 035 ）, but the side effects have no significant difference （ P 〉 0.05 ）. Conclusion ： The efficacy of deep hyperthemia combined with chemotherapy on non- small-cell lung cancer is better than pure chemotherapy.

关 键 词：热疗 化疗 非小细胞肺癌/晚期 

分 类 号：R734.2[医药卫生—肿瘤] R730.58[医药卫生—临床医学]